Prelude Therapeutics reports $99.5 mln net loss for 2025

Prelude Therapeutics Incorporated

10/03/2026 11:08

Overview

Precision oncology firm reported a net loss of $99.5 mln for 2025

Company received FDA clearance for IND application for PRT12396

Cash runway expected into Q2 2027 with $106 mln in cash and equivalents

Outlook

Prelude anticipates Phase 1 study of PRT12396 to start by Q2 2026

Company plans to file IND for PRT13722 in mid-2026

Prelude expects cash runway to last until Q2 2027

Result Drivers

FDA CLEARANCE - Prelude received FDA clearance for IND application for PRT12396, a mutant-selective JAK2V617F inhibitor, marking a key milestone in their strategic focus

KAT6A PROGRAM - Co is advancing its KAT6A degrader program with plans to file an IND in mid-2026 and initiate Phase 1 study in the second half of 2026

DEGRADER PAYLOADS - Prelude is developing novel degrader payloads for next-generation DACs, expanding potential partnerships and technological reach

Company press release: ID:nGNXsg6rZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.29
FY Net Income
-$99.50 mln
FY Income from Operations
-$104.57 mln
FY Operating Expenses
$116.71 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.00, about 29.4% above its March 9 closing price of $3.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)